CRISPR-Cas9 — Precision Gene Editing Becomes Possible
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) was originally observed as a bacterial immune system. In a landmark June 2012 paper in Science, Jennifer Doudna (UC Berkeley) and Emmanuelle Charpentier (now Humboldt University) demonstrated that the Cas9 protein could be programmed with a short RNA guide to cut DNA at any desired location in any genome. The simplicity was revolutionary: previous gene-editing tools (ZFNs, TALENs) required expensive, slow protein engineering for each new target. CRISPR required only designing a 20-letter RNA sequence. Within months, labs worldwide were applying CRISPR to human cells, mice, plants, and bacteria. Applications under development: Medicine — curing sickle-cell disease (first patient cured 2021), treating cancers, correcting blindness-causing mutations; Agriculture — disease-resistant crops, drought-tolerant varieties; Controversial — 2018 Chinese scientist He Jiankui edited human embryos to create HIV-resistant babies, triggering worldwide condemnation. Doudna and Charpentier shared the Nobel Prize in Chemistry in 2020 — the first all-female Nobel science prize. CRISPR raises profound ethical questions about germline editing (heritable changes to the human genome) and enhancement.
- Year: 2012 CE
- Category: Scientific
